In prostate cancer, luteolin exerts anticancer effects through various mechanisms such as suppression of androgen receptor expression and vascular endothelial growth factor receptor 2 (VEGFR-2) mediated angiogenesis at > 10 μM, and induction of cytotoxicity, apoptosis and cell cycle arrest via regulation of IGF-1/Akt pathway, Akt-Mdm2 pathway, epidermal growth factor signaling pathway and expression levels of miR-630 and miR-301 at > 10 μM [26–30]. This evidence concerns the gene MDM2 and prostate carcinoma.